Answers are grounded in this paper and cite their sources.
This review highlights advances in polymeric prodrugs for cancer therapy, improving drug retention at tumor sites and overcoming challenges.
Off-target effects of conventional chemotherapeutics often cause severe toxicities, posing a persistent clinical obstacle in cancer therapy. Nanodelivery systems can enhance tumor accumulation via the enhanced permeability and retention effect, yet reconciling systemic stability with rapid and site-specific drug release remains a longstanding challenge. Stimuli-responsive polymeric prodrugs, which integrate tumor microenvironment-responsive linkages with polymer-drug conjugation strategies, offer a promising solution by combining improved circulatory stability with selective activation at tumor sites. In this review, we summarize recent advances in the design of stimuli-responsive polymeric prodrugs according to characteristic tumor microenvironmental features, discuss their representative applications and mechanistic advantages, and outline the current limitations, translational challenges, and future directions in this field.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: